Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukemia inhibitory factor is mitogenic to osteoblasts

J Cornish1, K E Callon, S G Edgar

  • 1Department of Medicine, University of Auckland, New Zealand. j.cornish@auckland.ac.nz

Bone
|September 1, 1997
PubMed
Summary

Leukemia inhibitory factor (LIF) stimulates proliferation in bone-forming cells, not bone-resorbing osteoclasts. This growth factor enhances bone formation by targeting osteoprogenitor cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?

Expert opinion on drug safety·2022
Same author

The Moondance Bowel Cancer Project schools initiative.

Annals of the Royal College of Surgeons of England·2021
Same author

Bone-friendly lifestyle and the role of calcium or vitamin D supplementation.

Climacteric : the journal of the International Menopause Society·2021
Same author

Publisher Correction to: Development of the Asia Pacific Consortium on Osteoporosis (APCO) framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Where have all the appendicectomies gone?

Annals of the Royal College of Surgeons of England·2021
Same author

Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021

Area of Science:

  • Bone biology
  • Cellular regulation
  • Endocrinology

Background:

  • Leukemia inhibitory factor (LIF) is a cytokine regulating cell growth, produced by various tissues including bone.
  • Previous studies demonstrated LIF's role in increasing osteoclast number, bone formation, and DNA synthesis.

Purpose of the Study:

  • To identify the specific cells within intact bone that exhibit proliferative responses to LIF.
  • To differentiate between bone-forming and bone-resorbing cells affected by LIF.

Main Methods:

  • Simultaneous enzyme histochemistry and autoradiography techniques were employed.
  • Alkaline phosphatase staining was used to identify bone-forming cells.
  • [3H]thymidine incorporation measured DNA synthesis to detect proliferating cells.

Related Experiment Videos

Main Results:

  • LIF treatment resulted in a twofold increase in alkaline phosphatase-positive staining area (p = 0.0008).
  • A twofold increase in [3H]thymidine-positive cells was observed in LIF-treated bones (p = 0.0024).
  • Proliferating cells were localized with alkaline phosphatase or in the osteoprogenitor region, not with osteoclasts.

Conclusions:

  • LIF's mitogenic effects in bone are primarily directed towards bone-forming cells.
  • The study indicates LIF promotes proliferation in osteoprogenitor cells, contributing to bone formation.
  • LIF does not appear to stimulate proliferation in mature osteoclasts.